Ver anterior:
Reputation Institute’s 2018 US Pharma RepTrak
Amgen got a big win in May when the FDA approved its preventive migraine drug Aimovig, which is the first of a new class of medications that's going after the huge migraine market.
Swiss drug company Roche is still one of the biggest in the world. In February, it acquired Flatiron Health, a cancer technology startup for $1.9 billion.
BMS is making a big bet its new investments into immunotherapy-combination drug s for combating cancer.
The German pharmaceutical firm manufactures drugs not only for humans but for their pets as well.
The company is now partnering up with some other big names to develop anti-diabetic medication.
Lilly is the producer of Cymbalta, a drug widely used for depression.
The company was also part of the cohort that had to jump ship on its Alzheimer's drug.
AZ, known for producing Crestor - a drug that treats high cholesterol and triglyceride levels - saw a win in lung cancerdata in May this year, but suffered a setback from an Alzheimer's drug in June that failed to show signs of working.
The Israeli company is a huge manufacturer of generic drugs.
In December 2017, it cut 25% of its workforce, but its stock got a bump in February after Warren Buffett declared a stake in it.
Over the past year, Japanese drugmaker Takeda has been growing its global presence, first by sealing a deal with Ariad Pharmaceutics and then acquiring Shire, the maker of Adderall, for $64 billion.
It's been a bumpy year for Mylan.
The drugmaker faced scrutiny over its EpiPen recalls,followed by outcry over generic drug pricing.
In June, however, Mylan scored a key approval for a biosimilar version of the drug Neulasta, which could help save the US billions.
Famous for drugs like Keytruda, Merck has had a bit of a comeback as a winner at ASCO with its positive melanoma data. But the company has had its share of bad headlines as well. In May 2017, Merck paid $60.2 million to resolve a lawsuit about its practices to delay entrance of generic drugs into the market.
Merck was also accused that month of operating an anti-competition scheme.
In August 2017, Trump called out Merck's CEO about lowering drug prices and increasing transparency in their operations.
Merck, along with GSK and Pfizer were the only pharmaceutical companies to have a "weak" score, while the rest had "average" or "strong" reputations.
GSK just welcomed the first female big pharma CEO onboard in 2017.
With that, came a reshuffling of 40% of the company's top management team in a bid to bring in new ideas.
The drugmaker has seen increased competition in its core businesses: respiratory and HIV treatments. It entered into an open rivalry with Gilead over HIV drugs in November 2017.
In April, the company's shingles vaccine was recommended by the US Center for Disease Control.
However, in May, regulators in Europe and the US issued warnings about a link between the company's HIV drug, Tivicay, and certain birth defects. But just last month, the company's two drug HIV met goals in late-stage studies.
"At GSK, our purpose is to help people do more, feel better and live longer and we accomplish this with our innovative medicines and vaccines. We have a legacy of ensuring people have access to our medicines and our vaccines, and we lead the pharmaceutical industry in the fight against so-called super bugs - all of which has been recognized by the Access to Medicine Foundation," GSK said in an email statement to Business Insider.
Pfizer had the lowest reputational score among the pharmaceutical companies that Reputation Institute looked at, based on the general public's perception of product, prices and public hospitality. It was reported in May that Pfizer used charity to mask a heart drug price hike. Pfizer also had a huge role in the drug shortage crisis, according to Fortune.
The drug giant is now taking some new risks and dipping its toes into some uncharted scientific territories like gene therapy and cancer immunotherapy.
"Pfizer's reputation has remained consistent since 2017 and is on par with our multinational biopharmaceutical peers given the variance in reputation scores is limited. We look forward to continuing to educate our stakeholders about Pfizer's mission to discover new medicines and to ensure patients have access to them," Pfizer representatives said in an email statement to Business Insider.
(Ver)
No hay comentarios:
Publicar un comentario